DOCSLIB.ORG

Antimicrobial Medication Guide for Pediatric Cystic Fibrosis Patients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antimicrobial Medication Guide for Pediatric Cystic Fibrosis Patients Pediatric Pharmacy #: 984-974-6679 Blue Team Pharmacist Pager #: 123-7108 Antimicrobial Medication Guide for Pediatric Cystic Fibrosis Patients Oral Antibiotics *See NTM section for organism-specific dosing for mycobacterial infections. Drug Dosing Maximum Available preparations Other considerations single dose Amoxicillin/ 15 mg/kg TID 2000 mg 500mg*, 875mg tablets* 600mg/5mL for high clavulanic acid (standard dose) or 45 200mg, 400mg chewables* dose only mg/kg BID (high dose) XR tablets 1000mg 200mg/5mL, 400 mg/5mL suspension* ES suspension: 600 mg/5mL (less clavulanic acid) Cefpodoxime 5 mg/kg BID 200 mg 100mg, 200mg tablets 50mg/5mL, 100mg/5mL suspension Cefuroxime axetil 10-15 mg/kg BID 500 mg 125mg, 250mg*, 500mg Suspension and tablet (suspension) or tablets* are not interchangable 250-500mg BID 125mg/5mL, 250mg/5mL Suspension must be (tablet) suspension administered with food Cephalexin 25 mg/kg QID 1000 mg 250*, 500mg capsules* 125mg/5mL, 250mg/5mL suspension* Ciprofloxacin 20 mg/kg BID 1000 mg 100mg, 250mg*, 500mg*, Do not give oral 750mg tablets* suspension via G-tube 100 mg/mL, 250mg/5mL or NG tube suspension Hold tube feeds 1 hr 500mg, 1000mg XR tablets before and 2 hrs after administration Clindamycin 40 mg/kg/day divided 600 mg 75mg, 150mg*, 300mg capsules TID 75mg/5mL suspension* Dicloxacillin2 6.25-12.5mg/kg QID 500 mg 125mg, 250mg*, 500mg capsules* Doxycycline 1-2 mg/kg BID 100 mg 50mg, 100mg capsules* Avoid within 2hrs of 25mg/5mL suspension* antacids, Ca, Fe, Mg, and cholestyramine Levofloxacin < 5 yo: 10 mg/kg BID 750 mg 250mg*, 500mg*, 750mg Suspension should be > 5 yo: 10 mg/kg daily tablets* administered 1 hr 25mg/mL solution* before or 2hrs after eating Linezolid < 12 yo: 10 mg/kg Q8 600 mg 600mg tablet* Consider continuing q8 > 12yo: 10 mg/kg Q12 100mg/5mL suspension* hour dosing if > 12 yr but less than 45 kg Minocycline 4 mg/kg once, then 2 100 mg 50mg*, 75mg, 100mg capsules* Avoid within 2hrs of mg/kg Q12 antacids, Ca, Fe, Mg, and cholestyramine Rifampin 10 mg/kg Q12 600mg 150mg*, 300mg capsules* Do not use as 25mg/mL suspension* monotherapy; for synergy only Sulfamethoxazole/ 15-20 mg TMP/kg/day 320mg TMP 80 mg TMP+400 mg SMX tab*, Trimethoprim (SMX/TMP) divided Q8-Q12 160 mg TMP+800 mg SMX DS tab* 40mg TMP+200mg SMX/5mL suspension* Tedizolid^ 200 mg once daily+ 200 mg 200 mg tablet ^Requires approval by ID consult or Pediatric ID Stewardship for inpatient use *Indicates UNC formulary item + Adult dosing (pediatric dosing not available): for patients <40kg, consult pediatric pulmonary and/or ID/ASP pharmacist for dosing 1 Pediatric Pharmacy #: 984-974-6679 Blue Team Pharmacist Pager #: 123-7108 Intravenous Antibiotics *See NTM section for organism-specific dosing for mycobacterial infections. • Double-cover Pseudomonas, but do not combine anti-pseudomonal beta lactams, as they can be antagonistic • Initial doses for Tobramycin and Amikacin should be based on patients’ previous doses; see pharmacist consult note for past dosing information • If patient has not received aminoglycosides in the past, use the following guide for dosing Consider alternative dosing regimens for patients with lack of response to antibiotic expected to have activity – consult service pharmacist for appropriateness and availability Drug Traditional Dosing Alternative Dosing Maximum single Other considerations dose Aztreonam1,2* 50-75 mg/kg Q6 8-12 g/day Cefepime1,3* 50 mg/kg Q8 Intermittent: 50 mg/kg Q6 2000 mg Extended: 50 mg/kg Q8 (infused over 4 hours) Ceftaroline4* < 6 years: 8 mg/kg Q8 600mg > 6 years and <33 kg: 15 mg/kg Q8 > 33 kg (adolescent/adult): 600 mg Q8 Ceftazidime1,3* 200-400 mg/kg/day divided Continuous: 100-200 8-12 g/day Q6-8 mg/kg/day Ceftazidime/ 2.5 g q8+ (2g ceftazidime/500 2.5 g Only for MDR Gram negative avibactam*^ mg avibactam) pathogens; susceptibility must be documented prior to use Ceftolozane/ 3 g Q8+ (2g ceftolozane/1 g 3 g Only for MDR Gram negative tazobactam5*^ tazobactam) pathogens; susceptibility must be documented prior to use Cefuroxime* 75 mg/kg Q8 1500 mg Ciprofloxacin1,6* 10 mg/kg Q8 400 mg Clindamycin* 40 mg/kg/day divided Q8 2700 mg/day Colistin1,7*^ 3-5 mg/kg/day divided Q8 100mg Monitor renal function closely Can use up to 8 mg/kg/day Only for MDR Gram negative pathogens; susceptibility must be requested/ documented prior to use Imipenem/ 25 mg/kg Q6 1000 mg Cilastatin1,2* Levofloxacin1,6* < 5 yo: 10 mg/kg Q12 750 mg > 5 yo: 10 mg/kg daily Linezolid* < 12 yo: 10 mg/kg Q8 600 mg Consider continuing q 8 hour ≥ 12 yo: 10 mg/kg Q12 dosing if > 12 yr but less than 45 kg Meropenem1,2* 40 mg/kg Q8 Extended: 40 mg/kg q8h 2000 mg (infused over 3 hours) Oxacillin1* 50 mg/kg Q6 Continuous: 200mg/kg/day 2000 mg Piperacillin/ 100 mg/kg Q6 Extended: 100 mg/kg Q6 4000mg All doses are based on Tazobactam1,3,25* (infused over 3 hours) piperacillin (4.5g piperacillin component Continuous: 200-300 Zosyn®) mg/kg/day Tedizolid^ 200mg Q24 200mg Tobramycin* 10 mg/kg Q24 or previous total Draw levels at 2 and 8 hours (extended interval) daily dose after 2nd dose started Vancomycin11, 22* 15-20 mg/kg Q6-8 Continuous: 55-60 2000 mg Intermittent: Draw trough mg/kg/day (intermittent) prior to 4th dose; goal 15-20 mg/L Continuous: Draw random level after 24 hours; goal 20- 25 mg/L ^Requires approval by ID consult or Pediatric ID Stewardship for inpatient use *Indicates UNC formulary item + Adult dosing (pediatric dosing not available): for patients <40kg, consult pediatric pulmonary and/or ID/ASP pharmacist for dosing 2 Pediatric Pharmacy #: 984-974-6679 Blue Team Pharmacist Pager #: 123-7108 Nontuberculous Mycobacterium – Antibiotics *Typically start only one drug each day to assess for adverse effects from each drug Recommended Initial Regimen for Mycobacterium abscessus: 1. Clarithromycin or azithromycin 2. Amikacin 3. Cefoxitin, imipenem/cilastatin, tigecycline, or linezolid Recommended Initial Regimen for Mycobacterium avium complex (MAC): 1. Azithromycin 2. Ethambutol 3. Rifampin Drug Dosing Maximum dose Other considerations Amikacin13 (IV) 10-15 mg/kg IV daily 1500mg/dose Draw 2 and 8 hour levels with 2nd or 3rd dose; goal peak = 20-30 mg/L Audiology consult required at initiation Thrice weekly dosing can be considered for unique patient cases Amikacin21(inhalation) 250-500 mg inhaled daily-BID 500mg/dose Arikayce®: 590mg inhaled daily Azithromycin13,21 10-12 mg/kg PO daily 500mg/dose Consider obtaining drug levels at 2 and 6 hours Bedaquiline24^ Weeks 1-2: 400 mg PO daily Reserve for refractory NTM cases Weeks 3 and onward: 200 mg TIW Weight 20-32 kg: 200 mg PO daily x 2 weeks, then 100 mg TIW Weight > 32 kg: 400 mg PO daily x 2 weeks, then 200 mg TIW Cefoxitin13,21 Children: 50mg/kg IV TID 12g/day Adults: 200 mg/kg/day IV divided TID Clarithromycin13,21 7.5 mg/kg PO BID 500mg/dose Consider obtaining drug levels at 2 and 6 hours Clofazimine^ 50-100 mg PO daily 150 mg Reserve for refractory NTM cases (requires an IRB and IND) Ethambutol21 15 mg/kg PO daily Consider obtaining drug levels at 2 and 6 hours Imipenem/ cilastatin13,21(IV) 15-20 mg/kg IV BID 1000mg/dose Linezolid13,21(PO, IV) < 12 yo: 10 mg/kg Q8 600mg 1:1 PO to IV conversion ≥ 12 yo: 10 mg/kg daily-BID Consider concomitant vitamin B6 Minocycline21 Children: 2 mg/kg PO daily 200mg/dose Adults: 100mg PO BID Moxifloxacin21 7.5-10 mg/kg PO daily 400mg/dose Rifampin21 10-20 mg/kg PO daily < 50 kg: 450mg/day Significant potential for drug > 50 kg: 600mg/day interactions Consider obtaining drug levels at 2 and 6 hours SMX/TMP21 (PO, IV) 10-20 mg/kg TMP BID PO: 160mg TMP/dose Consider fluid status of patient when IV: 1440mg/dose utilizing IV formulation Tedizolid (PO, IV) 200 mg once daily PO/IV: 200 mg Tigecycline13,14,21 < 10 yo: 1.2 mg/kg IV Q12 50mg Recommend pre-medication with > 10 yo: 100mg loading dose, then ondansetron or other antiemetic 50mg IV daily-BID ^Requires approval by ID consult or Pediatric ID Stewardship for inpatient use *Indicates UNC formulary item + Adult dosing (pediatric dosing not available) 3 Pediatric Pharmacy #: 984-974-6679 Blue Team Pharmacist Pager #: 123-7108 Antifungals *These have lots of drug interactions! *Consult pharmacy for assistance transitioning between dosage forms. Drug Dosing Maximum Available oral initial preparations single dose Fluconazole 12 mg/kg x 1, then 6-12 mg/kg IV/PO 800mg 50mg*, 100mg*, 150mg*, Q24 200 mg tablets* 40mg/mL suspension* Itraconazole 5 mg/kg PO Q12 200 mg 100mg capsules* 50mg/5mL solution* Voriconazole (PO/IV) Loading doses: 350 mg 50mg*, 200mg tablets* < 12 yo OR 12-14 yo AND < 50 kg: 9 40mg/mL suspension* mg/kg IV Q12 x 2 doses > 12 yo AND > 50kg: 6 mg/kg IV Q12 x 2 doses Maintenance doses: < 12 yo: 9 mg/kg IV Q12 > 12 yo AND > 50kg: 4 mg/kg IV Q12 Posaconazole20 Suspension: 18-24 mg/kg/day divided Suspension: 40mg/mL suspension* QID 400mg 100mg DR tablet* Tablets: <13 yo: 10-15 mg/kg/day divided BID Tablets: > 13 yo: 6-8 mg/kg BID x 1 day, then 6- 300mg 8 mg/kg daily IV: 10-12 mg/kg BID x 1 day, then 10- 12 mg/kg daily Considerations for antifungal therapies: Fluconazole Itraconazole Posaconazole Voriconazole Renally Dose Yes No No No, but do not use IV Adjust formulation if CrCl<50 Drug PPIs: May decrease PPIs: May decrease PPIs: May decrease PPIs: May increase Interactions fluconazole levels itraconazole levels posaconazole levels voriconazole levels Meals Capsules: food increases Capsules: food increases Suspension: best absorption Food may decrease absorption absorption with a hiGh-fat meal and voriconazole absorption acidic beverage Solution: food decreases Solution: food decreases Give 1 hour before or 1 hour absorption.
Load more

Recommended publications
  • Therapeutic Alternatives for Drug-Resistant Cabapenemase- Producing Enterobacteria
    THERAPEUTIC ALTERNATIVES FOR MULTIDRUG-RESISTANT AND EXTREMELY All isolates resistant to carbapenems were evaluated Fig. 1: Susceptibility (%) of Carbapenemase-producing MDRE Fig. 3: Susceptibility (%) of VIM-producing MDRE to Alternative DRUG-RESISTANT CABAPENEMASE- for the presence of genes encoding carbapenemases to Alternative Antibiotics Antibiotics PRODUCING ENTEROBACTERIA OXA-48-like, KPC, GES, NDM, VIM, IMP and GIM. M. Almagro*, A. Kramer, B. Gross, S. Suerbaum, S. Schubert. Max Von Pettenkofer Institut, Faculty of Medicine. LMU Munich, München, Germany. RESULTS BACKROUND 44 isolates of CPE were collected: OXA-48 (n=29), VIM (n=9), NDM-1 (n=5), KPC (n=1) and GES (n=1). The increasing emergence and dissemination of carbapenem-resistant gram-negative bacilli has From the 44 CPE isolates, 26 isolates were identified reduced significantly the options for sufficient as Klebsiella pneumoniae (68% of the OXA-48 CPE), 8 Fig. 2: Susceptibility (%) of OXA-48-producing MDRE to Fig. 4: Susceptibility (%) of NDM-producing MDRE to Alternative antibiotic therapy. The genes encoding most of these as Escherichia coli, 6 as Enterobacter cloacae, 2 as Alternative Antibiotics Antibiotics carbapenemases reside on plasmids or transposons Citrobacter freundii,1 as Providencia stuartii and 1 as carrying additional resistance genes which confer Morganella morganii. multidrug resistance to the isolates. 31 isolates (70%) were causing an infection, including urinary tract infection (20%), respiratory tract MATERIALS AND METHODS infection (18%), abdominal infection (18%), bacteraemia (9%) and skin and soft tissue infection In the present study, we tested the in vitro activity of (5%). 13 isolates were believed to be colonizers. antimicrobial agents against a well-characterized c o l l e c t i o n o f c a r b a p e n e m a s e - p r o d u c i n g Isolates were classified as 32 MDRE and 13 XDRE.
    [Show full text]
  • Antibiotic Assay Medium No. 3 (Assay Broth) Is Used for Microbiological Assay of Antibiotics. M042
    HiMedia Laboratories Technical Data Antibiotic Assay Medium No. 3 (Assay Broth) is used for M042 microbiological assay of antibiotics. Antibiotic Assay Medium No. 3 (Assay Broth) is used for microbiological assay of antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 5.000 Beef extract 1.500 Yeast extract 1.500 Dextrose 1.000 Sodium chloride 3.500 Dipotassium phosphate 3.680 Potassium dihydrogen phosphate 1.320 Final pH ( at 25°C) 7.0±0.2 **Formula adjusted, standardized to suit performance parameters Directions Suspend 17.5 grams in 1000 ml distilled water. Heat if necessary to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Advice:Recommended for the Microbiological assay of Amikacin, Bacitracin, Capreomycin, Chlortetracycline,Chloramphenicol,Cycloserine,Demeclocycline,Dihydrostreptomycin, Doxycycline, Gentamicin, Gramicidin, Kanamycin, Methacycline, Neomycin, Novobiocin, Oxytetracycline, Rolitetracycline, Streptomycin, Tetracycline, Tobramycin, Trolendomycin and Tylosin according to official methods . Principle And Interpretation Antibiotic Assay Medium is used in the performance of antibiotic assays. Grove and Randall have elucidated those antibiotic assays and media in their comprehensive treatise on antibiotic assays (1). Antibiotic Assay Medium No. 3 (Assay Broth) is used in the microbiological assay of different antibiotics in pharmaceutical and food products by the turbidimetric method. Ripperre et al reported that turbidimetric methods for determining the potency of antibiotics are inherently more accurate and more precise than agar diffusion procedures (2). Turbidimetric antibiotic assay is based on the change or inhibition of growth of a test microorganims in a liquid medium containing a uniform concentration of an antibiotic. After incubation of the test organism in the working dilutions of the antibiotics, the amount of growth is determined by measuring the light transmittance using spectrophotometer.
    [Show full text]
  • Antimicrobial Stewardship Guidance
    Antimicrobial Stewardship Guidance Federal Bureau of Prisons Clinical Practice Guidelines March 2013 Clinical guidelines are made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant these guidelines for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient-specific. Consult the BOP Clinical Practice Guidelines Web page to determine the date of the most recent update to this document: http://www.bop.gov/news/medresources.jsp Federal Bureau of Prisons Antimicrobial Stewardship Guidance Clinical Practice Guidelines March 2013 Table of Contents 1. Purpose ............................................................................................................................................. 3 2. Introduction ...................................................................................................................................... 3 3. Antimicrobial Stewardship in the BOP............................................................................................ 4 4. General Guidance for Diagnosis and Identifying Infection ............................................................. 5 Diagnosis of Specific Infections ........................................................................................................ 6 Upper Respiratory Infections (not otherwise specified) ..............................................................................
    [Show full text]
  • Automated Hilic-MS/MS Method for Therapeutic Drug Monitoring of Aminoglycoside Antibiotics and Vancomycin
    Automated HILiC-MS/MS Method for Therapeutic Drug Monitoring of Aminoglycoside Antibiotics and Vancomycin Mikaël LEVI1, Daisuke KAWAKAMI2, Jun WATANABE1 1 SHIMADZU Corporation, MS Business Unit, Kyoto, Japan; 2 SHIMADZU Corporation, Clinical & Biotechnology Business Unit, Kyoto, Japan Area Ratio Area Ratio y = 0.005292846x² + 0.04278182x - 0.004441359 y = 0.001371438x² + 0.02132510x + 0.00002051234 6.0 4.50 1. Introduction R² = 0.9974212 R = 0.9987098 R² = 0.9990104 R = 0.9995051 4.25 5.5 Curve Fit: Default (Quadratic) Curve Fit: Default (Quadratic) Weighting: 1/C 4.00 Weighting: Default (1/C^2) Zero: Default (Not Forced) Zero: Default (Not Forced) 5.0 3.75 3.50 4.5 Aminoglycoside antibiotics are used for treatment of severe infections, especially in the case of Arbekacin 3.25 Kanamycin 4.0 3.00 2.75 3.5 Gram-negative bacilli infection. However, aminoglycosides have narrow therapeutic indexes due to 2.50 3.0 2.25 2.00 2.5 their nephrotoxicity. Therefore, the benefit of therapeutic drug monitoring (TDM) for aminoglycoside 1.75 2.0 1.50 1.25 1.5 has been well-established. Vancomycin, a glycopeptide antibiotic, often used with aminoglycosides 1.00 1.0 0.75 0.50 0.5 because of their synergism, is also nephrotoxic and need to be monitored as well. 0.25 0.0 0.00 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 30.0 32.5 35.0 37.5 40.0 42.5 45.0 47.5 50.0 Conc.Ratio (mg/L) Conc.Ratio (mg/L) While LC-MS/MS is now considered as the gold standard method for TDM, many clinical laboratories Area Ratio Area Ratio 13 y = 0.0003193042x² + 0.2404682x - 0.001638089 y = 0.00002521235x² + 0.01160575x - 0.0007537159 R² = 0.9995769 R = 0.9997884 0.65 R² = 0.9997885 R = 0.9998942 12 Curve Fit: Default (Quadratic) 0.60 Curve Fit: Quadratic still use immunoassays.
    [Show full text]
  • Empirical Antimicrobial Therapy for Children with Cystic Fibrosis
    Empirical antimicrobial therapy for children with Cystic Fibrosis Document ID CHQ-GDL-01073 Version no. 2.0 Approval date 17/12/2020 Executive sponsor Executive Director of Medical Services Effective date 17/12/2020 Director Respiratory Medicine Review date 17/12/2022 Author/custodian Director Infection Management and Prevention Service, Immunology and Rheumatology Supersedes 1.1 Applicable to All Children’s Health Queensland staff Authorisation Executive Director Clinical Services (QCH) Purpose This guideline provides Children’s Health Queensland (CHQ) recommendations for empirical antimicrobial therapy for children with Cystic Fibrosis (CF), for inpatient and outpatient management. Scope This guideline provides information for CHQ staff caring for paediatric CF patients. Related documents Procedures, Guidelines, Protocols • CHQ Paediatric Therapeutic Drug Monitoring – Tobramycin/Gentamicin • CHQ Paediatric Therapeutic Drug Monitoring - Vancomycin • CHQ@Home Outpatient Parenteral Antimicrobial Therapy Prescribing, Administration and monitoring guideline • CHQ-PROC-01036 Antimicrobial: Prescribing, Management and Stewardship and CHQ Antimicrobial Restriction list • CHQ-PROC-63223 Management of patients with cystic fibrosis • CHQ-GDL-01061 Immunisation Guideline for Medically at Risk Children • CHQ-GDL-01076 Paediatric antibiotic allergy assessment, testing and de-labelling • CHQ-GDL-70047 Clinical guidelines for the care of children and adolescents with Cystic Fibrosis - Volume 1: Respiratory Care Guideline Empirical antimicrobial therapy
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Gentamicin, Tobramycin, Netilmicin, Or Amikacin and Carbenicillin Or Ticarcillin LARRY K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 1979, p. 592-596 Vol. 15, No. 4 0066-4804/79/04-0592/05$02.00/0 Effect of Time and Concentration Upon Interaction Between Gentamicin, Tobramycin, Netilmicin, or Amikacin and Carbenicillin or Ticarcillin LARRY K. PICKERING* AND PAM GEARHART Program in Infectious Diseases and Clinical Microbiology and Department ofPediatrics, The University of Texas Medical School, Houston, Texas 77030 Received for publication 18 January 1978 An aminoglycoside antibiotic and carbenicillin or ticarcillin are widely used in the treatment of patients with gram-negative bacillus infections. This study evaluated the effect of time upon in vitro interaction between mixtures of four aminoglycosides at two concentrations with carbenicillin or ticarcillin at four concentrations. By linear regression analysis, the inactivation of each aminogly- coside was shown to be directly proportional to the concentration of carbencillin (P < 0.001). Inactivation was significantly (P < 0.01) greater for gentamicin and tobramycin than for amikacin or netilmicin at all carbenicillin concentrations. At carbenicillin concentrations of 300 and 600 i.g/ml, significantly (P < 0.005) less inactivation of amikacin occurred when compared to netilmicin. Ticarcillin pro- duced a significant (P < 0.025) inactivation of gentamicin and tobramycin, with inactivation being directly proportional to ticarcillin concentration. No inactiva- tion ofamikacin or netilmicin activity occurred unless the ticarcillin concentration was 600 ,ug/ml. No significant change in aminoglycoside activity occurred when stored with ticarcillin or carbenicillin at concentrations ranging from 100 to 600 ug/ml at -70°C for 56 days. When an aminoglycoside and carbenicillin or ticarcillin are indicated in patients with renal failure, this study supports the use of ticarcillin with either amikacin or netilmicin.
    [Show full text]
  • Trend Analysis of Antibiotics Consumption Using WHO Aware Classification in Tertiary Care Hospital
    International Journal of Basic & Clinical Pharmacology Bhardwaj A et al. Int J Basic Clin Pharmacol. 2020 Nov;9(11):1675-1680 http:// www.ijbcp.com pISSN 2319-2003 | eISSN 2279-0780 DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20204493 Original Research Article Trend analysis of antibiotics consumption using WHO AWaRe classification in tertiary care hospital Ankit Bhardwaj*, Kaveri Kapoor, Vivek Singh Saraswathi institute of Medical Sciences, Pilakhuwa, Hapur, Uttar Pradesh, India Received: 21 August 2020 Accepted: 21 September 2020 *Correspondence: Dr. Ankit Bhardwaj, Email: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Aim of the study was to assess trend in antibiotics consumption pattern from 2016 to 2019 using AWaRe classification, ATC and Defined daily dose methodology (DDD) in a tertiary care hospital. Antibiotics are crucial for treating infectious diseases and have significantly improved the prognosis of patients with infectious diseases, reducing morbidity and mortality. The aim of the study is to classify the antibiotic based on WHO AWaRe classification and compare their four-year consumption trends. The study was conducted at a tertiary care center, Pilakhuwa, Hapur. Antibiotic procurement data for a period of 4 years (2016-2019) was collected from the Central medical store. Methods: This is a retrospective time series analysis of systemic antibiotics with no intervention at patient level. Antibiotic procurement was taken as proxy for consumption assuming that same has been used.
    [Show full text]
  • In Vitro Antimicrobial Susceptibilities of Francisella Tularensis Subsp. Holarctica Isolates from Tularemia Outbreaks That Occur
    antibiotics Article In Vitro Antimicrobial Susceptibilities of Francisella tularensis subsp. holarctica Isolates from Tularemia Outbreaks That Occurred from the End of the 20th Century to the 2020s in Spain Sonia Martínez-Martínez 1, Elías-Fernando Rodríguez-Ferri 1, David Rodríguez-Lázaro 2 , Marta Hernández 3 , José-Ignacio Gómez-Campillo 4, María del Carmen Martínez-Nistal 4, María-Isabel Fernández-Natal 5, María-José García-Iglesias 1 , Olga Mínguez-González 6 and César-Bernardo Gutiérrez-Martín 1,* 1 Departmento de Sanidad Animal, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24007 León, Spain; [email protected] (S.M.-M.); [email protected] (E.-F.R.-F.); [email protected] (M.-J.G.-I.) 2 Unidad de Microbiología, Departamento de Biotecnología y Ciencia de los Alimentos, Facultad de Ciencias, and Research Centre for Emerging Pathogens and Global Health, University of Burgos, 09001 Burgos, Spain; [email protected] 3 Laboratorio de Biología Molecular y Microbiología, Instituto Tecnológico Agrario de Castilla y Citation: Martínez-Martínez, S.; León (ITACyL), 47071 Valladolid, Spain; [email protected] Rodríguez-Ferri, E.-F.; 4 Laboratorio Regional de Sanidad Animal, Villaquilambre, 24193 León, Spain; [email protected] (J.-I.G.-C.); Rodríguez-Lázaro, D.; Hernández, [email protected] (M.d.C.M.-N.) 5 M.; Gómez-Campillo, J.-I.; Jefe de Servicio de Análisis Clínicos/Coordinadora del Laboratorio de Diagnóstico Clínico del Complejo Martínez-Nistal, M.d.C.; Asistencial Universitario, Hospital Universitario de León, 24071 León, Spain; [email protected] Fernández-Natal, M.-I.; 6 Jefe de Servicio de Sanidad Animal, Consejería de Agricultura, Ganadería y Desarrollo Rural, Dirección García-Iglesias, M.-J.; General de Producción Agropecuaria, Junta de Castilla y León, 47014 Valladolid, Spain; [email protected] Mínguez-González, O.; * Correspondence: [email protected]; Tel.: +34-98729-1203 Gutiérrez-Martín, C.-B.
    [Show full text]
  • NORM Normgvet
    2O16 NORM NORM-VET Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway DESIGN, FORSIDE: IDA SKAAR IDA FORSIDE: DESIGN, – SVANEGODKJENT TRYKKSAK – 241 762 241 – TRYKKSAK SVANEGODKJENT – ISSN: 1502-2307 (print) / 1890-9965 (electronic) AS MEDIA LUNDBLAD 2016 NORM NORM-VET Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway ISSN: 1502-2307 (print) / 1890-9965 (electronic) Any use of data from NORM/NORM-VET 2016 should include specific reference to this report. Suggested citation: NORM/NORM-VET 2016. Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway. Tromsø / Oslo 2017. ISSN:1502-2307 (print) / 1890-9965 (electronic). This report is available at www.vetinst.no and www.antibiotikaresistens.no 1 CONTENTS NORM / NORM-VET 2016 CONTRIBUTORS AND PARTICIPANTS Editors: Gunnar Skov Simonsen NORM, Univ. Hosp. North Norway Anne Margrete Urdahl NORM-VET, Norwegian Veterinary Institute Authors: Per Espen Akselsen Antibiotic usage in humans [email protected] KAS, Haukeland Univ. Hosp. Cecilie Torp Andersen Candida spp. [email protected] Oslo Univ. Hosp. Elisabeth Astrup MRSA in humans [email protected] Norw. Inst. of Pub. Health Hege Salvesen Blix Antibiotic usage in humans [email protected] Norw. Inst. of Pub. Health Dominique Caugant Meningococci [email protected] Norw. Inst. of Pub. Health Petter Elstrøm MRSA in humans [email protected] Norw. Inst. of Pub. Health Hege Enger MRSA in humans [email protected] St. Olav Univ. Hosp. Frode Width Gran MRSA in humans [email protected] St. Olav Univ. Hosp. Kari Grave Antibiotic usage in animals [email protected] Norw.
    [Show full text]
  • Myasthenia Gravis Or Lambert-Eaton Myasthenia Syndrome – Medicines That May Affect Patients
    CLINICAL GUIDELINE Myasthenia Gravis or Lambert-Eaton Myasthenia Syndrome – Medicines that may affect patients A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments. Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty. If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient. Version Number: 1 Does this version include n/a changes to clinical advice: Date Approved: 11th July 2018 Date of Next Review: 30th July 2021 Lead Author: Lesley Murray Approval Group: Medicines Utilisation Subcommittee of ADTC Important Note: The Intranet version of this document is the only version that is maintained. Any printed copies should therefore be viewed as ‘Uncontrolled’ and as such, may not necessarily contain the latest updates and amendments. Information for healthcare professionals Medicines that may affect patients with Myasthenia Gravis or Lambert-Eaton Myasthenic Syndrome There are certain medicines that have been reported to worsen or induce myasthenia gravis (MG), often by increasing muscular weakness, and should be used with caution in patients with this condition. The list of medicines in table 1 has been compiled to assist prescribers in the decision making process when prescribing medicines for patients with myasthenia gravis. The medicines in this list have been classed according to those which should be: ▲ ▲Absolutely contraindicated ▲ Avoided Used with caution Probably safe with patient monitoring.
    [Show full text]
  • Package Leaflet: Information for the User
    Package leaflet: Information for the user Amikacin 250 mg/ml Injection Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Amikacin Injection is and what it is used for 2. What you need to know before you use Amikacin Injection 3. How to use Amikacin Injection 4. Possible side effects 5. How to store Amikacin Injection 6. Contents of the pack and other information 1. What Amikacin injection is and what it is used for Amikacin Injection is one of a group of antibiotic medicines called ‘aminoglycosides’. Amikacin Injection is used in the treatment of serious infections caused by bacteria sensitive to amikacin. 2. Before you use Amikacin Injection Do not use Amikacin Injection • if you have shown signs of hypersensitivity (severe allergy) to amikacin, or any of the other ingredients listed in section 6, in the past • if you suffer from a disorder called myasthenia gravis (severe weakness of certain muscles of the body) Tell your doctor if any of the above applies to you before this medicine is used. Warnings and precautions Talk to your doctor before using Amikacin Injection • if you have kidney problems • if you have hearing difficulties or tinnitus (ringing or buzzing in the ears) • if you have shown signs of allergy to any of the antibiotics related to amikacin (aminoglycosides) in the past • if you have a known allergy to sulphites Tell your doctor if any of the above applies to you before this medicine is used.
    [Show full text]